All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
The Psoriasis and Psoriatic Arthritis Hub was pleased to speak to Steven R. Feldman, Wake Forest University, Winston-Salem, US. We asked, Why do we have low adherence to psoriasis treatments and how do we improve that?
Why do we have low adherence to psoriasis treatments and how do we improve that?
Feldman begins by pointing out that adherence to treatment is not the default and should not be assumed. It is then discussed how treatments can differ between localized and generalized psoriasis, and how doctors can increase treatment adherence in their patients.
Your opinion matters
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox